Akero rises on planned release of mid-stage data on liver disease asset
Hawkinsight
2025-01-25 09:04:57
1.55W
Rasi Bhadramani
- Akero Therapeutics (NASDAQ:AKRO) is up ~5% in after-hours trading Friday after announcing it will hold a conference call Jan. 27 to discuss topline results from a phase 2b study of efruxifermin in patients with compensated cirrhosis due to metabolic
Disclaimer: The views in this article are from the original Creator and do not represent the views or position of Hawk Insight. The content of the article is for reference, communication and learning only, and does not constitute investment advice. If it involves copyright issues, please contact us for deletion.
